Commitments to implement a patent-linkage system notifying originators of generic filings as well as patent-term extensions to compensate for regulatory and patent review periods are key measures in a section on pharmaceutical intellectual-property protection included in "Phase One" of a trade agreement signed between China and the US on 15 January.
Pharmaceutical data protection is also included in the deal. (Also see "Trade, IP And Oncology Deals: What You Need...





